Cardiol Therapeutics (CT9) AI Stock Analysis

0 Followers

Cardiol Therapeutics

(Frankfurt:CT9)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageVery low debt reduces financial risk and limits mandatory interest obligations while the company funds clinical development. This conservative leverage profile preserves flexibility to allocate capital toward research, trials, and regulatory work without a large debt burden.

Negative Factors

Pre-Revenue BusinessThe absence of meaningful revenue means Cardiol has not yet demonstrated commercial demand or an operating model funded by customers. Until a candidate is approved and launched, financial performance will remain dependent on clinical progress rather than recurring product sales.

Cardiol Therapeutics (CT9) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 121.87M
Dividend Yield: ―
Average Volume (3M): 4,344
Price to Earnings (P/E): -4.2
Beta (1Y): 0.71
Revenue Growth: ―
EPS Growth: 33.62%
Country: Germany
Employees: 18
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Business Overview & Revenue Model

Company Description

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship pr...

Cardiol Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:CT9 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:CPH	74Outperform	CAD 346.41M	8.44	22.74%	―	3.18%	140.09%
TSE:GUD	74Outperform	CAD 1.18B	77.56	2.03%	―	36.15%	―
TSE:BHC	61Neutral	CAD 4.41B	-3.68	58.90%	―	10.07%	-328.97%
TSE:MDP	60Neutral	CAD 162.79M	-48.83	-4.69%	―	-3.16%	-345.50%
TSE:MPH	53Neutral	CAD 38.61M	-5.36	-54.73%	―	38.25%	-450.85%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:CT9 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:CT9	Cardiol Therapeutics Inc.	0.96	0.13	15.66%
TSE:BHC	Bausch Health Companies	11.91	2.64	28.48%
TSE:GUD	Knight Therapeutics	12.03	5.88	95.61%
TSE:CPH	Cipher Pharmaceuticals Inc	13.71	0.43	3.20%
TSE:MPH	Medicure Inc	3.80	2.51	194.57%
TSE:MDP	Medexus Pharmaceuticals	5.31	2.62	97.40%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cardiol Therapeutics AI Stock Analysis